MorphoSys AG-Product Pipeline Review-2015

MorphoSys AG-Product Pipeline Review-2015

  • Products Id :- GMDHC06830CDB
  • |
  • Pages: 40
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

MorphoSys AG-Product Pipeline Review-2015


Global Markets Direct's, 'MorphoSys AG-Product Pipeline Review-2015', provides an overview of the MorphoSys AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MorphoSys AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of MorphoSys AG including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of MorphoSys AG's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the MorphoSys AG's pipeline products

Reasons To Buy

Evaluate MorphoSys AG's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of MorphoSys AG in its therapy areas of focus

Identify new drug targets and therapeutic classes in the MorphoSys AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of MorphoSys AG and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of MorphoSys AG

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of MorphoSys AG and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

MorphoSys AG Snapshot 5

MorphoSys AG Overview 5

Key Information 5

Key Facts 5

MorphoSys AG-Research and Development Overview 6

Key Therapeutic Areas 6

MorphoSys AG-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Pipeline Products-Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

MorphoSys AG-Pipeline Products Glance 16

MorphoSys AG-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

MorphoSys AG-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

MorphoSys AG-Drug Profiles 20

MOR-208 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

MOR-202 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Monoclonal Antibodies for MRSA Infections 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Monoclonal Antibodies for Undisclosed Indication 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibody for Oncology 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibody to Antagonize GPCR for Inflammation 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

MorphoSys AG-Pipeline Analysis 28

MorphoSys AG-Pipeline Products by Target 28

MorphoSys AG-Pipeline Products by Route of Administration 29

MorphoSys AG-Pipeline Products by Molecule Type 30

MorphoSys AG-Pipeline Products by Mechanism of Action 31

MorphoSys AG-Recent Pipeline Updates 32

MorphoSys AG-Dormant Projects 36

MorphoSys AG-Discontinued Pipeline Products 37

Discontinued Pipeline Product Profiles 37

MOR-203 37

MOR-101 37

MOR-102 37

MorphoSys AG-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

MorphoSys AG, Key Information 5

MorphoSys AG, Key Facts 5

MorphoSys AG-Pipeline by Indication, 2015 8

MorphoSys AG-Pipeline by Stage of Development, 2015 9

MorphoSys AG-Monotherapy Products in Pipeline, 2015 10

MorphoSys AG-Partnered Products in Pipeline, 2015 11

MorphoSys AG-Partnered Products/ Combination Treatment Modalities, 2015 12

MorphoSys AG-Out-Licensed Products in Pipeline, 2015 14

MorphoSys AG-Out-Licensed Products/ Combination Treatment Modalities, 2015 15

MorphoSys AG-Phase II, 2015 16

MorphoSys AG-Phase I, 2015 17

MorphoSys AG-Preclinical, 2015 18

MorphoSys AG-Discovery, 2015 19

MorphoSys AG-Pipeline by Target, 2015 28

MorphoSys AG-Pipeline by Route of Administration, 2015 29

MorphoSys AG-Pipeline by Molecule Type, 2015 30

MorphoSys AG-Pipeline Products by Mechanism of Action, 2015 31

MorphoSys AG-Recent Pipeline Updates, 2015 32

MorphoSys AG-Dormant Developmental Projects,2015 36

MorphoSys AG-Discontinued Pipeline Products, 2015 37

MorphoSys AG, Subsidiaries 38

List of Figures

MorphoSys AG-Pipeline by Top 10 Indication, 2015 7

MorphoSys AG-Pipeline by Stage of Development, 2015 9

MorphoSys AG-Monotherapy Products in Pipeline, 2015 10

MorphoSys AG-Partnered Products in Pipeline, 2015 11

MorphoSys AG-Pipeline by Top 10 Target, 2015 28

MorphoSys AG-Pipeline by Top 10 Route of Administration, 2015 29

MorphoSys AG-Pipeline by Top 10 Molecule Type, 2015 30

MorphoSys AG-Pipeline Products by Top 10 Mechanism of Action, 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of MorphoSys AG; MorphoSys AG - Key Therapeutics; MorphoSys AG - Pipeline Overview and Promising Molecules; MorphoSys AG - News; MorphoSys AG - Latest Updates; MorphoSys AG - Pipeline; MorphoSys AG - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101985
Site License
USD 3000 INR 203970
Corporate User License
USD 4500 INR 305955



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]